Role of regulatory T-cells during hepatitis C infection: From the acute phase to post-transplantation recurrence

Digestive and Liver Disease

Volumn 47, Issue 11, 2015, Pages 913-917

  Barjon, Clément ^a   Dahlqvist, Géraldine ^a   Calmus, Yvon ^a,b   Conti, Filomena ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Hepatitis C virus; Regulatory T cells; Transplantation

Indexed keywords

ADAPTIVE IMMUNITY; ARTICLE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; REGULATORY T LYMPHOCYTE; VIRUS INFECTION; CHRONIC HEPATITIS C; COMPLICATION; HEPACIVIRUS; IMMUNOLOGY; LIVER CIRRHOSIS; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE;

HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; T-LYMPHOCYTES, REGULATORY;

EID: 84945451124     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.06.014     Document Type: Article

References (65)

1. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology 1995, 155:1151-1164.
2. Liu W., Putnam A.L., Xu-Yu Z., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. Journal of Experimental Medicine 2006, 203:1701-1711.
3. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
4. Shimizu J., Yamazaki S., Takahashi T., et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunology 2002, 3:135-142.
5. Birebent B., Lorho R., Lechartier H., et al. Suppressive properties of human CD4+ CD25+ regulatory T cells are dependent on CTLA-4 expression. European Journal of Immunology 2004, 34:3485-3496.
6. Malek T.R., Yu A., Zhu L., et al. IL-2 family of cytokines in T regulatory cell development and homeostasis. Journal of Clinical Immunology 2008, 28:635-639.
7. Thornton A.M., Piccirillo C.A., Shevach E.M. Activation requirements for the induction of CD4+ CD25+ T cell suppressor function. European Journal of Immunology 2004, 34:366-376.
8. Thornton A.M., Shevach E.M. Suppressor effector function of CD4+ CD25+ immunoregulatory T cells is antigen nonspecific. Journal of Immunology 2000, 164:183-190.
9. Gregori S., Goudy K.S., Roncarolo M.G. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Frontiers in Immunology 2012, 3:30.
10. Lin X., Chen M., Liu Y., et al. Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. International Journal of Clinical and Experimental Pathology 2013, 6:116-123.
11. Weiss J.M., Bilate A.M., Gobert M., et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. Journal of Experimental Medicine 2012, 209(Suppl. 1):1723-1742.
12. Groux H., O'Garra A., Bigler M., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
13. Roncarolo M.G., Gregori S., Battaglia M., et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews 2006, 212:28-50.
14. Rahmoun M., Foussat A., Groux H., et al. Enhanced frequency of CD18- and CD49b-expressing T cells in peripheral blood of asthmatic patients correlates with disease severity. International Archives of Allergy and Immunology 2006, 140:139-149.
15. Gagliani N., Magnani C.F., Huber S., et al. Coexpression of CD49b and -3 identifies human and mouse T regulatory type 1 cells. Nature Medicine 2013, 19:739-746.
16. Bacchetta R., Sartirana C., Levings M.K., et al. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. European Journal of Immunology 2002, 32:2237-2245.
17. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. Journal of Immunology 1999, 163:5211-5218.
18. Boettler T., Spangenberg H.C., Neumann-Haefelin C., et al. T cells with a CD4+ CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. Journal of Virology 2005, 79:7860-7867.
19. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2011, 17:107-115.
20. Hajarizadeh B., Grebely J., Dore G.J. Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology & Hepatology 2013, 10:553-562.
21. Missale G., Bertoni R., Lamonaca V., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. Journal of Clinical Investigation 1996, 98:706-714.
22. Gerlach J.T., Diepolder H.M., Jung M.C., et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999, 117:933-941.
23. Urbani S., Amadei B., Fisicaro P., et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006, 44:126-139.
24. Semmo N., Day C.L., Ward S.M., et al. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005, 41:1019-1028.
25. Smyk-Pearson S., Tester I.A., Klarquist J., et al. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. Journal of Virology 2008, 82:1827-1837.
26. Kared H., Fabre T., Bedard N., et al. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathogens 2013, 9:e1003422.
27. Larrubia J.R., Moreno-Cubero E., Lokhande M.U., et al. Adaptive immune response during hepatitis C virus infection. World Journal of Gastroenterology: WJG 2014, 20:3418-3430.
28. Sugimoto K., Ikeda F., Stadanlick J., et al. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003, 38:1437-1448.
29. Perrella A., Vitiello L., Atripaldi L., et al. Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. Gut 2006, 55:1370-1371.
30. Heeg M.H., Ulsenheimer A., Gruner N.H., et al. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. Gastroenterology 2009, 137:1280-1288. e1-6.
31. Smyk-Pearson S., Golden-Mason L., Klarquist J., et al. Functional suppression by FoxP3+ CD4+ CD25(high) regulatory T cells during acute hepatitis C virus infection. Journal of Infectious Diseases 2008, 197:46-57.
32. Cabrera R., Tu Z., Xu Y., et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40:1062-1071.
33. Ebinuma H., Nakamoto N., Li Y., et al. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. Journal of Virology 2008, 82:5043-5053.
34. Yang J.H., Zhang Y.X., Yu R.B., et al. CD4+ CD25+ regulatory T cells suppress CD4+ T cell responses in patients with persistent hepatitis C virus infection. Zhonghua nei ke za zhi 2006, 45:29-33.
35. Claassen M.A., de Knegt R.J., Tilanus H.W., et al. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. Journal of Hepatology 2010, 52:315-321.
36. Wang J.P., Zhang Y., Wei X., et al. Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 2010, 118:261-270.
37. Chang J.B., Xue R., Zhou Z.X., et al. Prediction of antiviral efficacy in patients with chronic hepatitis C by changes in forkhead box protein 3 levels. Experimental and Therapeutic Medicine 2014, 8:165-168.
38. Riezu-Boj J.I., Larrea E., Aldabe R., et al. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. Journal of Hepatology 2011, 54:422-431.
39. Higashitani K., Kanto T., Kuroda S., et al. Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. Journal of Gastroenterology 2013, 48:660-670.
40. Ayers C.L., Firan M., Pillai V., et al. Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection. Viral Immunology 2011, 24:119-129.
41. Hall C.H., Kassel R., Tacke R.S., et al. HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGF-beta. PLoS ONE 2010, 5:e12154.
42. Ji X.J., Ma C.J., Wang J.M., et al. HCV-infected hepatocytes drive CD4+ CD25+ Foxp3+ regulatory T-cell development through the Tim-3/Gal-9 pathway. European Journal of Immunology 2013, 43:458-467.
43. Mengshol J.A., Golden-Mason L., Arikawa T., et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS ONE 2010, 5:e9504.
44. Barjon C., Niki T., Verillaud B., et al. A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses. Infectious Agents and Cancer 2012, 7:16.
45. Dominguez-Villar M., Fernandez-Ponce C., Munoz-Suano A., et al. Up-regulation of FOXP3 and induction of suppressive function in CD4+ Jurkat T-cells expressing hepatitis C virus core protein. Clinical Science 2012, 123:15-27.
46. Fernandez-Ponce C., Dominguez-Villar M., Aguado E., et al. CD4+ primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells. PLOS ONE 2014, 9:e85191.
47. Krishnadas D.K., Li W., Kumar R., et al. HCV-core and NS3 antigens play disparate role in inducing regulatory or effector T cells in vivo: implications for viral persistence or clearance. Vaccine 2010, 28:2104-2114.
48. Perrella A., Arenga G., Pisaniello D., et al. Elevated CD4+/CD25+ T-cell frequency and function during hepatitis C virus recurrence after liver transplantation. Transplantation Proceedings 2009, 41:1761-1766.
49. Bolacchi F., Sinistro A., Ciaprini C., et al. Increased hepatitis C virus (HCV)-specific CD4+ CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clinical and Experimental Immunology 2006, 144:188-196.
50. Itose I., Kanto T., Kakita N., et al. Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis. Journal of Viral Hepatitis 2009, 16:844-852.
51. Sturm N., Thelu M.A., Camous X., et al. Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. Journal of Hepatology 2010, 53:25-35.
52. Li S., Vriend L.E., Nasser I.A., et al. Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis. Hepatology 2012, 56:2094-2105.
53. Delhem N., Cottrez F., Carpentier A., et al. Role of the Regulatory T lymphocytes in hepatitis C fibrosis progression. Bulletin du cancer 2008, 95:1029-1038.
54. Langhans B., Kramer B., Louis M., et al. Intrahepatic IL-8 producing Foxp3(+)CD4(+) regulatory T cells and fibrogenesis in chronic hepatitis C. Journal of Hepatology 2013, 59:229-235.
55. Carpentier A., Conti F., Stenard F., et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009, 9:2102-2112.
56. Fabien S., Olivier M., Khaldoun G., et al. CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation. BioMed Research International 2014, 2014:290878.
57. Basha H.I., Subramanian V., Seetharam A., et al. Characterization of HCV-specific CD4+ Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011, 11:775-785.
58. Baron U., Floess S., Wieczorek G., et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. European Journal of Immunology 2007, 37:2378-2389.
59. Taubert R., Hardtke-Wolenski M., Noyan F., et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. Journal of Hepatology 2014, 61:1106-1114.
60. Kobayashi T., Nakatsuka K., Shimizu M., et al. Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Immunology 2012, 137:259-270.
61. Langhans B., Nischalke H.D., Arndt S., et al. Ribavirin exerts differential effects on functions of CD4+ Th1, Th2, and regulatory T cell clones in hepatitis C. PLoS ONE 2012, 7:e42094.
62. Bohne F., Londono M.C., Benitez C., et al. HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. Science Translational Medicine 2014, 6:242ra81.
63. Kaplan D.E., Ikeda F., Li Y., et al. Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. Journal of Hepatology 2008, 48:903-913.
64. Accapezzato D., Francavilla V., Paroli M., et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. Journal of Clinical Investigation 2004, 113:963-972.
65. Alatrakchi N., Graham C.S., van der Vliet H.J., et al. Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. Journal of Virology 2007, 81:5882-5892.